Next Science Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXS.AX research report →
Price Chart
About the company
Next Science Limited operates as an innovative medical technology company, committed to researching, developing, and commercializing advanced solutions that combat the detrimental effects of biofilms on human health in both the United States and Australia. The firm's product development is underpinned by its proprietary Xbio Technology platform. Its diverse portfolio includes SURGX, an antimicrobial gel designed for managing surgical infections; BACTISURE, a specialized wound lavage formulated to eliminate biofilm; BlastX, an antimicrobial wound gel that not only eradicates bacteria but also guards against recolonization, all while sustaining a moist healing environment; and XPERIENCE, a convenient, no-rinse antimicrobial solution aimed at preventing surgical site infections.
- CEO
- Matthew Franco Myntti
- IPO
- 2019
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on NXS.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.43M
- P/E
- -2.86
- PEG
- -0.07
- P/S
- 1.33
- P/B
- 8.80
- EV/EBITDA
- -3.46
- Div Yield
- 100.00%
- Gross Margin
- 80.83%
- Op Margin
- -45.16%
- Net Margin
- -46.40%
- ROE
- -130.18%
- ROIC
- -165.73%
Latest fiscal year · YoY change
- Revenue
- $22.82M+2.9%
- Gross Profit
- $18.44M+13.6%
- Op Income
- $-10,304,109
- Net Income
- $-10,586,018+56.8%
- EPS
- $-0.04+47.8%
- OCF Growth
- +47.1%
- FCF Growth
- +46.4%
- 52W High
- $0.15
- 52W Low
- $0.06
- 50D MA
- $0.14
- 200D MA
- $0.13
- Beta
- 1.22
- RSI (14)
- 54
- Avg Volume
- 367.91K
No earnings-call transcripts are available for NXS.AX yet.
- Free Float
- 47.6%
- Shares Outstanding
- 292.63M
- Float Shares
- 139.25M
Our NXS.AX coverage
Recent articles, reports, and earnings notes.
No research on NXS.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXS.AX report →